Trends in Immunology
Feature ReviewAntibody B cell responses in HIV-1 infection
Section snippets
Antibodies against HIV-1
More than a century ago, Von Behring and Kitasato provided the first evidence on the role of the humoral response in host protection against infectious agents using serum therapy experiments against diphtheria and tetanus toxins [1]. ‘Briefly expressed, serum therapy works through anti-bodies’ explained Emil Von Behring (http://www.nobelprize.org). We now know that antibodies are valuable immunotherapeutics for a wide range of infectious diseases 2, 3, that they can confer mother-to-child
Systemic and mucosal antibody responses to HIV-1
The initial antibody response to HIV-1 can be detected as immune complexes as early as ∼1 week post-infection [15]. In the following days, circulating anti-gp41 antibodies are produced, followed by production of anti-gp120 antibodies a few weeks later, but none of these antibodies are capable of neutralizing the infecting viral strain (autologous virus) [15]. The first autologous neutralizing antibodies appear several months post-infection and although they are unable to neutralize heterologous
Multiple viral strategies for disrupting and evading the immune response
HIV-1 infection induces major perturbations in B cell development, physiology, and function that likely interfere with the establishment of a normal antiviral humoral response. Deregulation of B cell differentiation and function during HIV-1 infection is now well documented and consists of a variety of abnormalities, which are also associated with pathological changes in lymphoid tissues supporting B cell immune response (follicular hyperplasia and germinal centers alterations) such as: (i) B
Features of HIV-1 neutralizing antibodies
In the early 1990s, first-generation HIV-1 bNAbs were isolated using Epstein–Barr virus transformation and phage display methods 77, 78, 79, 80, 81, 82. Their extensive molecular characterization improved our knowledge of the host immune response to HIV-1 by identifying important sites of vulnerability, antibody structure-to-function relations, and numerous viral escape mechanisms as described above [83]. Nevertheless, the uncommon nature of the antibodies (unnatural IgH and IgL pairing for
Development of next generation HIV-1 bNAbs
Genetic and biological host factors that determine or influence the generation of HIV-1 bNAbs are not fully understood, and are an area of active investigation. From an immunological standpoint, genetic predisposition to the natural control of HIV-1 (HIV-1 controller phenotype) is principally linked to certain HLA class I alleles predicted to enable efficient effector CD8+ T cell responses [106]. Whether specific genetic traits are associated with the development of bNAbs in Elite neutralizers
Antiviral activity of broadly HIV-1 neutralizing antibodies and therapeutic potential
The antiviral activity of HIV-1 antibodies is typically measured in vitro using cell-free pseudovirus particles and reporter cell lines, such as the HeLa-derived TzMbl cell [137]. In these assays, which measure the inhibition of free virus binding to cellular receptors and/or of viral fusion (Figure 4), first-generation bNAbs can achieve neutralization breadth but only several orders of magnitude less than the recently isolated bNAbs, which can neutralize up to 95% of HIV-1 strains at low
Concluding remarks
Humoral immune responses are fundamental to the host protection against pathogens, and rely on the extraordinary diversity of antibody molecules that ensure the recognition of a theoretically infinite number of foreign antigens. Since the beginning of the AIDS epidemic 30 years ago, intensive research efforts have been engaged to dissect the interplay between HIV-1 and neutralizing antibodies. However, only recently did the discovery and characterization at a molecular level of broadly
Acknowledgments
We are grateful to Jean-Philippe Julien and Ian A. Wilson (The Scripps Research Institute) for providing us the structural model used in Figure 2, and to Caroline Eden (Icahn School of Medicine at Mount Sinai) for helpful comments and manuscript editing. This work was supported by the European Research Council (ERC) – Seventh Framework Program (ERC-2013-StG 337146). H.M. was supported by the G5 Institut Pasteur Program and the Milieu Intérieur Program (ANR-10-LABX-69-01).
Glossary
- Germinal centers
- germinal centers are specialized microenvironments within secondary lymphoid organs that support the maturation, proliferation, and differentiation of B lymphocytes during T cell dependent immune responses. These microanatomical structures are divided into light and dark zones; in the dark zone, B cells expand and diversify their antigen receptors through somatic hypermutation (that potentially increases antibody affinity) and class-switching (that alters antibody effector
References (180)
- et al.
Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology
N. Biotechnol.
(2011) Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients
Nature
(1985)B cell responses to HIV-1 infection and vaccination: pathways to preventing infection
Trends Mol. Med.
(2011)B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection
Nat. Commun.
(2010)Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice
Cell
(2014)HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life
Mucosal Immunol.
(2013)Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM
Immunity
(1998)HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis
Mucosal Immunol.
(2009)Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
Immunity
(2011)- et al.
Emerging concepts on T follicular helper cell dynamics in HIV infection
Trends Immunol.
(2014)
Structural insights on the role of antibodies in HIV-1 Vaccine and therapy
Cell
B-cell tolerance checkpoints in health and autoimmunity
Curr. Opin. Immunol.
A method for identification of HIV gp140 binding memory B cells in human blood
J. Immunol. Methods
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers
Immunity
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers
Immunity
Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike
Cell Rep.
Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization
Cell
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies
Immunity
A History of Immunology
The growth and potential of human antiviral monoclonal antibody therapeutics
Nat. Biotechnol.
Maternal antibodies, childhood infections, and autoimmune diseases
N. Engl. J. Med.
Vaccines: correlates of vaccine-induced immunity
Clin. Infect. Dis.
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
Science
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex
Nature
Identifying epitopes of HIV-1 that induce protective antibodies
Nat. Rev. Immunol.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
N. Engl. J. Med.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial
N. Engl. J. Med.
Towards an HIV cure: a global scientific strategy
Nat. Rev. Immunol.
Antibodies in HIV-1 vaccine development and therapy
Science
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
J. Virol.
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses
J. Virol.
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
J. Virol.
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
J. Virol.
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Proc. Natl. Acad. Sci. U.S.A.
Antibody neutralization and escape by HIV-1
Nature
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection
Proc. Natl. Acad. Sci. U.S.A.
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection
J. Virol.
Characteristics of the earliest cross-neutralizing antibody response to HIV-1
PLoS Pathog.
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
J. Virol.
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
J. Virol.
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
J. Virol.
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
J. Virol.
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Aids
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
J. Virol.
Early development of broadly neutralizing antibodies in HIV-1-infected infants
Nat. Med.
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization
Science
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals
J. Virol.
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
PLoS Pathog.
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Nature
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies
Proc. Natl. Acad. Sci. U.S.A.
Cited by (84)
Bystander cd4 t-cell death is inhibited by broadly neutralizing anti-hiv antibodies only at levels blocking cell-to-cell viral transmission
2021, Journal of Biological ChemistryPrevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine
2021, Biomedicine and PharmacotherapyCitation Excerpt :Additionally, a mutation in SARS-CoV-2 spike protein such as D614 G may increase its infectivity and make the vaccine less effective [224]. In parallel, the B cells, which produce antibodies, are also subject to the phenomena of somatic mutations at the origin of antibody variants exhibiting increasingly optimized activities [225]. There is, therefore, competition between the immune system and the virus.
The memory of the fatty acid system
2020, Progress in Lipid ResearchHIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria
2023, Nature Communications